Review



ccr2 small molecule inhibitor rs504393  (Tocris)


Bioz Verified Symbol Tocris is a verified supplier
Bioz Manufacturer Symbol Tocris manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Tocris ccr2 small molecule inhibitor rs504393
    a Subcutaneous tumor growth in syngeneic mice injected with NA13 cells ( n = 6 biologically independent mice per group). Data representative of two independent experiments. Statistical significance was determined by two-way ANOVA. Arrows indicate dates in which anti-PD-1 treatment was given. Mean ± SD. b Individual tumor volumes as a function of time. Each line represents a single mouse ( n = 10 or 11 biologically independent mice per group). c Waterfall plot showing change in NA13 tumor volume on endpoint day 30 post tumor injection compared to baseline prior to treatment with and without <t>CCR2</t> antagonist <t>RS504393</t> and/or anti-PD-1 treatment. Starting on day 14, mice were treated daily with CCR2 antagonist RS503393, and every three days with anti-PD-1.
    Ccr2 Small Molecule Inhibitor Rs504393, supplied by Tocris, used in various techniques. Bioz Stars score: 95/100, based on 129 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ccr2 small molecule inhibitor rs504393/product/Tocris
    Average 95 stars, based on 129 article reviews
    ccr2 small molecule inhibitor rs504393 - by Bioz Stars, 2026-03
    95/100 stars

    Images

    1) Product Images from "Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy"

    Article Title: Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy

    Journal: Communications Biology

    doi: 10.1038/s42003-020-01441-y

    a Subcutaneous tumor growth in syngeneic mice injected with NA13 cells ( n = 6 biologically independent mice per group). Data representative of two independent experiments. Statistical significance was determined by two-way ANOVA. Arrows indicate dates in which anti-PD-1 treatment was given. Mean ± SD. b Individual tumor volumes as a function of time. Each line represents a single mouse ( n = 10 or 11 biologically independent mice per group). c Waterfall plot showing change in NA13 tumor volume on endpoint day 30 post tumor injection compared to baseline prior to treatment with and without CCR2 antagonist RS504393 and/or anti-PD-1 treatment. Starting on day 14, mice were treated daily with CCR2 antagonist RS503393, and every three days with anti-PD-1.
    Figure Legend Snippet: a Subcutaneous tumor growth in syngeneic mice injected with NA13 cells ( n = 6 biologically independent mice per group). Data representative of two independent experiments. Statistical significance was determined by two-way ANOVA. Arrows indicate dates in which anti-PD-1 treatment was given. Mean ± SD. b Individual tumor volumes as a function of time. Each line represents a single mouse ( n = 10 or 11 biologically independent mice per group). c Waterfall plot showing change in NA13 tumor volume on endpoint day 30 post tumor injection compared to baseline prior to treatment with and without CCR2 antagonist RS504393 and/or anti-PD-1 treatment. Starting on day 14, mice were treated daily with CCR2 antagonist RS503393, and every three days with anti-PD-1.

    Techniques Used: Injection



    Similar Products

    ccr2 small molecule inhibitor rs504393  (Tocris)
    95
    Tocris ccr2 small molecule inhibitor rs504393
    a Subcutaneous tumor growth in syngeneic mice injected with NA13 cells ( n = 6 biologically independent mice per group). Data representative of two independent experiments. Statistical significance was determined by two-way ANOVA. Arrows indicate dates in which anti-PD-1 treatment was given. Mean ± SD. b Individual tumor volumes as a function of time. Each line represents a single mouse ( n = 10 or 11 biologically independent mice per group). c Waterfall plot showing change in NA13 tumor volume on endpoint day 30 post tumor injection compared to baseline prior to treatment with and without <t>CCR2</t> antagonist <t>RS504393</t> and/or anti-PD-1 treatment. Starting on day 14, mice were treated daily with CCR2 antagonist RS503393, and every three days with anti-PD-1.
    Ccr2 Small Molecule Inhibitor Rs504393, supplied by Tocris, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ccr2 small molecule inhibitor rs504393/product/Tocris
    Average 95 stars, based on 1 article reviews
    ccr2 small molecule inhibitor rs504393 - by Bioz Stars, 2026-03
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    a Subcutaneous tumor growth in syngeneic mice injected with NA13 cells ( n = 6 biologically independent mice per group). Data representative of two independent experiments. Statistical significance was determined by two-way ANOVA. Arrows indicate dates in which anti-PD-1 treatment was given. Mean ± SD. b Individual tumor volumes as a function of time. Each line represents a single mouse ( n = 10 or 11 biologically independent mice per group). c Waterfall plot showing change in NA13 tumor volume on endpoint day 30 post tumor injection compared to baseline prior to treatment with and without CCR2 antagonist RS504393 and/or anti-PD-1 treatment. Starting on day 14, mice were treated daily with CCR2 antagonist RS503393, and every three days with anti-PD-1.

    Journal: Communications Biology

    Article Title: Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy

    doi: 10.1038/s42003-020-01441-y

    Figure Lengend Snippet: a Subcutaneous tumor growth in syngeneic mice injected with NA13 cells ( n = 6 biologically independent mice per group). Data representative of two independent experiments. Statistical significance was determined by two-way ANOVA. Arrows indicate dates in which anti-PD-1 treatment was given. Mean ± SD. b Individual tumor volumes as a function of time. Each line represents a single mouse ( n = 10 or 11 biologically independent mice per group). c Waterfall plot showing change in NA13 tumor volume on endpoint day 30 post tumor injection compared to baseline prior to treatment with and without CCR2 antagonist RS504393 and/or anti-PD-1 treatment. Starting on day 14, mice were treated daily with CCR2 antagonist RS503393, and every three days with anti-PD-1.

    Article Snippet: CCR2 small molecule inhibitor RS504393 (Tocris) was given daily at 2 mg/kg by oral gavage to B16F10 mice and intraperitoneally to E0771 and NA13 mice.

    Techniques: Injection